{"id":"https://openalex.org/W4380084558","doi":"https://doi.org/10.1002/hon.3164_388","title":"Combined autologous CD30.CAR\u2010T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)","display_name":"Combined autologous CD30.CAR\u2010T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4380084558","doi":"https://doi.org/10.1002/hon.3164_388"},"language":"en","primary_location":{"id":"doi:10.1002/hon.3164_388","doi":"https://doi.org/10.1002/hon.3164_388","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3164_388","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_388","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_388","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039574726","display_name":"Sairah Ahmed","orcid":"https://orcid.org/0000-0001-7302-8299","observed_orcids":["https://orcid.org/0000-0001-7302-8299"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Ahmed","raw_affiliation_strings":["MD Anderson Cancer Center, University of Texas, Department of Lymphoma/Myeloma and Stem Cell Transplantation, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, University of Texas, Department of Lymphoma/Myeloma and Stem Cell Transplantation, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063781871","display_name":"Matthew Genyeh Mei","orcid":"https://orcid.org/0000-0002-1109-6955","observed_orcids":["https://orcid.org/0000-0002-1109-6955"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Mei","raw_affiliation_strings":["City of Hope Medical Center, Division of Lymphoma, Duarte, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Medical Center, Division of Lymphoma, Duarte, California, USA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068290727","display_name":"David Matthew Kurtz","orcid":"https://orcid.org/0000-0002-6382-4651","observed_orcids":["https://orcid.org/0000-0002-6382-4651"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. M. Kurtz","raw_affiliation_strings":["Stanford University, Stanford, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Stanford, California, USA","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038261300","display_name":"Amer Beitinjaneh","orcid":"https://orcid.org/0000-0002-1661-5865","observed_orcids":["https://orcid.org/0000-0002-1661-5865"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Beitinjaneh","raw_affiliation_strings":["Slyvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Slyvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":null,"display_name":"N. S. Grover","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. S. Grover","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036591050","display_name":"Carlos A. Ramos","orcid":"https://orcid.org/0000-0002-4004-7837","observed_orcids":["https://orcid.org/0000-0002-4004-7837"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. A. Ramos","raw_affiliation_strings":["Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, Texas, USA","institution_ids":["https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076624501","display_name":"Jacob J. Chabon","orcid":"https://orcid.org/0000-0003-1820-9737","observed_orcids":["https://orcid.org/0000-0003-1820-9737"]},"institutions":[{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. J. Chabon","raw_affiliation_strings":["Foresight Diagnostics, Aurora, Colorado, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foresight Diagnostics, Aurora, Colorado, USA","institution_ids":["https://openalex.org/I921990950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025882626","display_name":"Andr\u00e9 Schultz","orcid":"https://orcid.org/0000-0002-2909-3154","observed_orcids":["https://orcid.org/0000-0002-2909-3154"]},"institutions":[{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Schultz","raw_affiliation_strings":["Foresight Diagnostics, Aurora, Colorado, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foresight Diagnostics, Aurora, Colorado, USA","institution_ids":["https://openalex.org/I921990950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068037005","display_name":"C. Ding","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"C. Ding","raw_affiliation_strings":["Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016426367","display_name":"Aung Myo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"A. Myo","raw_affiliation_strings":["Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007420876","display_name":"Ash A. Alizadeh","orcid":"https://orcid.org/0000-0002-5153-5625","observed_orcids":["https://orcid.org/0000-0002-5153-5625"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. A. Alizadeh","raw_affiliation_strings":["Stanford University, Stanford, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Stanford, California, USA","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062966348","display_name":"Ivan David Horak","orcid":"https://orcid.org/0009-0003-8726-4016","observed_orcids":["https://orcid.org/0009-0003-8726-4016"]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"I. D. Horak","raw_affiliation_strings":["Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108237118","display_name":"HE Heslop","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. E. Heslop","raw_affiliation_strings":["Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, Texas, USA","institution_ids":["https://openalex.org/I181547552"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4220,"currency":"USD","value_usd":4220},"apc_paid":null,"fwci":0.2428,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.50525844,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":96},"biblio":{"volume":"41","issue":"S2","first_page":"524","last_page":"525"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0357000008225441,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9639999866485596},{"id":"https://openalex.org/keywords/classical-hodgkin-lymphoma","display_name":"classical Hodgkin lymphoma","score":0.8870000243186951},{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.906000018119812},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6600000262260437},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.5509999990463257},{"id":"https://openalex.org/keywords/lymphodepletion-chemotherapy","display_name":"lymphodepletion chemotherapy","score":0.8349999785423279},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.8360000252723694},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.7829999923706055},{"id":"https://openalex.org/keywords/ctdna","display_name":"ctDNA","score":0.6890000104904175},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.8209999799728394},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5860000252723694},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.4749999940395355}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8769418001174927},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8694107532501221},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.6618808507919312},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5996373891830444},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5819482207298279},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5386675596237183},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4828932285308838},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3266856074333191},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2600458264350891},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.12664636969566345},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/hon.3164_388","doi":"https://doi.org/10.1002/hon.3164_388","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3164_388","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_388","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1002/hon.3164_388","doi":"https://doi.org/10.1002/hon.3164_388","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3164_388","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3164_388","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4380084558.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310106518","https://openalex.org/W4417019939","https://openalex.org/W3214626906","https://openalex.org/W4310127384","https://openalex.org/W4310089922","https://openalex.org/W4391935241","https://openalex.org/W4281868964","https://openalex.org/W7134117006","https://openalex.org/W3128943205","https://openalex.org/W4417002055"],"abstract_inverted_index":{"Introduction:":[0],"Autologous":[1],"CD30.CAR-T":[2,91,122,199,261,324],"therapy":[3,58,100,208],"has":[4],"demonstrated":[5,315],"promising":[6,320],"antitumor":[7,87],"activity":[8,88],"with":[9,102,111,187,198,220,260,281,295,326],"favorable":[10,316],"safety":[11,85,317],"profile":[12,318],"in":[13,46,94,285,328],"relapsed":[14],"or":[15,158,250,378,415,431,439,456,484,496,504,512,521,548,557],"refractory":[16],"(r/r)":[17],"classical":[18],"Hodgkin":[19,23,366],"Lymphoma":[20],"(cHL)":[21],"patients.":[22],"Reed-Sternberg":[24],"cells,":[25],"the":[26,61,345,354,373],"target":[27],"of":[28,36,54,63,89,114,121,132,174,192,248,265,323,334,338,369],"CD30.CAR-T,":[29],"frequently":[30],"overexpress":[31],"PD-L1/PD-L2.":[32],"Checkpoint":[33],"inhibitors":[34],"(CPI)":[35],"PD-1,":[37],"including":[38],"nivolumab":[39],"(nivo),":[40],"have":[41],"shown":[42],"effective":[43],"and":[44,56,66,86,92,168,194,262,273,319,344,347],"safe":[45],"r/r":[47,95,329],"cHL.":[48],"Pre-clinical":[49],"studies":[50],"suggest":[51],"that":[52],"combination":[53],"CPI":[55],"CAR-T":[57,64],"could":[59],"enhance":[60],"survival":[62],"cells":[65],"promote":[67],"tumor":[68],"cell":[69,156],"death.":[70],"Methods:":[71],"A":[72,172],"single-arm,":[73],"phase":[74],"1b,":[75],"multicenter":[76],"study":[77],"(NCT#":[78],"05352828)":[79],"is":[80,342],"being":[81],"conducted":[82],"to":[83,105,162,233,292,372],"evaluate":[84],"combined":[90,325],"nivo":[93,133,160,327],"cHL":[96,330],"patients":[97,104,176,184,196,214,222,237,258,287,300,331,340],"after":[98,332],"frontline":[99,335],"failure,":[101],"15":[103,175,339],"be":[106,351],"enrolled.":[107],"Patients":[108,147],"are":[109,134],"treated":[110,186,197,259],"2":[112,130,190],"cycles":[113,131,165,191,264],"nivo,":[115,193,266],"followed":[116,137],"by":[117,124,138,141],"a":[118],"single":[119],"infusion":[120],"preceded":[123],"lymphodepletion":[125],"(LD)":[126],"chemotherapy.":[127,235],"An":[128],"additional":[129,164],"then":[135],"given,":[136],"response":[139,271],"assessment":[140],"PET/CT":[142],"per":[143,166],"Lugano":[144],"2014":[145],"criteria.":[146],"without":[148,246],"progressive":[149],"disease":[150,276],"may":[151],"undergo":[152],"either":[153],"autologous":[154],"stem":[155],"transplant":[157],"continue":[159],"up":[161],"6":[163],"physician":[167],"patient":[169],"preference.":[170],"Results:":[171],"total":[173],"were":[177,185,228,268,290],"enrolled":[178,341],"(Table":[179],"1).":[180],"To":[181],"date,":[182,293],"all":[183,294],"at":[188,216,305,353],"least":[189,217],"10":[195],"(median":[200],"dose:":[201],"2.4":[202],"[range:":[203],"2.0\u20132.7]":[204],"\u00d7108":[205],"cells/m2).":[206],"Combined":[207],"was":[209,254,279,358],"well":[210],"tolerated.":[211],"86.7%":[212],"(13/15)":[213],"experienced":[215],"one":[218,274],"AE":[219],"46.7%":[221],"having":[223],"grade":[224],"\u22653":[225],"AEs":[226],"which":[227,244],"hematologic":[229],"toxicities":[230],"mainly":[231],"due":[232],"LD":[234],"Two":[236],"had":[238,302],"cytokine":[239],"release":[240],"syndrome":[241],"(Grade":[242],"1),":[243],"resolved":[245],"use":[247],"steroid":[249],"tocilizumab.":[251],"No":[252],"neurotoxicity":[253],"observed.":[255],"Among":[256],"5":[257],"4":[263,269],"there":[267],"complete":[270],"(CR)":[272],"stable":[275],"(SD).":[277],"ctDNA-MRD":[278,304,348],"assessed":[280],"PhasED-Seq":[282],"(Foresight":[283],"Diagnostics)":[284],"3":[286,299],"where":[288],"samples":[289],"available":[291],"radiographic":[296],"CR.":[297],"All":[298],"(100%)":[301],"undetectable":[303],"this":[306],"timepoint,":[307],"demonstrating":[308],"deep":[309],"molecular":[310],"response.":[311],"Conclusion:":[312],"Preliminary":[313],"data":[314,349],"anti-tumor":[321],"responses":[322],"failure":[333],"therapy.":[336],"Evaluation":[337],"ongoing,":[343],"clinical":[346],"will":[350],"presented":[352],"meeting.":[355],"The":[356],"research":[357],"funded":[359],"by:":[360],"Tessa":[361,382,396,443,459,469,478,507,515,551,569,584],"Therapeutics":[362,466,472,508,516,552,570,585],"Keywords:":[363],"Cellular":[364],"therapies,":[365],"lymphoma":[367],"Conflicts":[368],"interests":[370],"pertinent":[371],"abstract.":[374],"S.":[375,436],"Ahmed":[376],"Consultant":[377,414,430,438,455,520,556],"advisory":[379,416,432,440,457,522,558],"role:":[380,417,433,441,458,523,559],"Chimagen,":[381,395],"Therapeutics,":[383,385,444,446,460,462,470,479,575,583],"Myeloid":[384],"ADC":[386,445],"therapeutics,":[387],"KITE/Gilead":[388],"Research":[389,402,449,467,541,580],"funding:":[390,403,450,468,542,581],"Seattle":[391],"Genetics,":[392],"Merck,":[393],"Xencor,":[394],"Therapeutic":[397],"M.":[398,412],"Mei":[399],"Honoraria:":[400],"Novartis":[401],"BMS":[404,543],"Other":[405,473],"remuneration:":[406,474],"Speaker":[407],"Bureau:":[408],"Morphosys,":[409],"SeaGen":[410],"D.":[411,545],"Kurtz":[413],"Foresight":[418,426,487,491,499,524,536],"Diagnostics,":[419,525,537],"Genentech,":[420,463,532],"Roche,":[421,530],"Adaptive":[422,527],"Biotechnologies":[423,579],"Stock":[424,489,534,571],"ownership:":[425,490,535,572],"Diagnostics":[427,488,492,500],"A.":[428,453,493,509,517,518],"Beitinjaneh":[429],"Kite/Gilead":[434],"N.":[435],"Grover":[437],"Novartis,":[442,464,568],"Kite,":[447],"Caribou":[448],"Genentech":[451],"C.":[452,501],"Ramos":[454],"Athenex":[461,471],"CRISPR":[465],"Royalties":[475],"&":[476],"Patents:":[477],"J.":[480,481],"Chabon":[482],"Employment":[483,495,503,511,547],"leadership":[485,497,505,513,549],"position:":[486,498,506,514,550],"Schultz":[494],"Ding":[502],"Myo":[510],"Alizadeh":[519],"Cibermed,":[526,538],"Biotechnologies,":[528,563],"Gilead,":[529,539],"BMS,":[531],"Karyopharm":[533],"Syncopation":[540],"I.":[544],"Horak":[546],"H.":[553],"E.":[554],"Heslop":[555],"Ankarys,":[560],"Fresh":[561,577],"Wind":[562,578],"Gilead":[564],"Biosciences,":[565],"GlaxoSmithKline,":[566],"Millenium,":[567],"Allovir,":[573],"Marker":[574],"Coregen,":[576],"Kuur":[582]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2023-06-10T00:00:00"}